Arbutus Biopharma (ABUS) Restructuring Costs (2015 - 2025)
Arbutus Biopharma (ABUS) posted Restructuring Costs of $303000.0 for Q4 2025, up 209.18% sequentially from $98000.0 in Q3 2025, and up 218.95% YoY from $95000.0 in Q4 2024.
Powered by 
Analysis
Arbutus Biopharma (ABUS) Restructuring Costs (2015 - 2025) Analysis & Trends
Arbutus Biopharma has reported Restructuring Costs for 6 years, with the latest figure at $303000.0 in Q4 2025.
- Quarterly Restructuring Costs rose 218.95% year-over-year to $303000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $12.8 million (down 20.46% YoY) and the FY2025 annual result came in at $12.9 million, up 247.82% from the prior year.
- Restructuring Costs improved to $303000.0 in Q4 2025 per ABUS's latest filing, from $98000.0 in the prior quarter.
- Over five years, Restructuring Costs peaked at $12.4 million in Q2 2025 and troughed at $95000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Arbutus Biopharma | 1.02 Bn | 923.36 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 303,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Jun 30, 2025 | 165,000.00 |
| Mar 31, 2025 | 12.37 Mn |
| Dec 31, 2024 | 95,000.00 |
| Sep 30, 2024 | 3.63 Mn |
| Jun 30, 2020 | 7,000.00 |
| Mar 31, 2020 | 57,000.00 |
| Dec 31, 2019 | 123,000.00 |
| Sep 30, 2019 | 182,000.00 |
| Jun 30, 2019 | -266,000.00 |
| Mar 31, 2019 | 4.90 Mn |
| Dec 31, 2018 | 1.09 Mn |
| Sep 30, 2018 | -492,000.00 |
| Jun 30, 2018 | 2.58 Mn |
| Mar 31, 2018 | 1.62 Mn |
| Jun 30, 2015 | 361,000.00 |
| Mar 31, 2015 | 9.30 Mn |